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Increased plasma concentrations of angiotension II (Ang II) have been implicated in atherogenesis.
To examine this relationship directly, we infused Ang II or vehicle for 1 month via osmotic
minipumps into mature apoE–/– mice. These doses of Ang II did not alter arterial blood pressure, body
weight, serum cholesterol concentrations, or distribution of lipoprotein cholesterol. However, Ang
II infusions promoted an increased severity of aortic atherosclerotic lesions. These Ang II–induced
lesions were predominantly lipid-laden macrophages and lymphocytes; moreover, Ang II promoted
a marked increase in the number of macrophages present in the adventitial tissue underlying lesions.
Unexpectedly, pronounced abdominal aortic aneurysms were present in apoE–/– mice infused with
Ang II. Sequential sectioning of aneurysmal abdominal aorta revealed two major characteristics: an
intact artery that is surrounded by a large remodeled adventitia, and a medial break with pronounced
dilation and more modestly remodeled adventitial tissue. Although no atherosclerotic lesions were
visible at the medial break point, the presence of hyperlipidemia was required because infusions of
Ang II into apoE+/+ mice failed to generate aneurysms. These results demonstrate that increased plasma concentrations of Ang II have profound and rapid effects on vascular pathology when combined
with hyperlipidemia, in the absence of hemodynamic influences.
J. Clin. Invest. 105:1605–1612 (2000).

Introduction
There is considerable evidence implicating a role for
angiotensin II (Ang II) in the atherogenic process. The
measurement of Ang II in plasma is technically difficult and fraught with experimental artifacts; thus,
increased concentrations of Ang II in plasma have been
inferred by the activity of the enzymes that generate
this octapeptide. In humans, there is associative evidence supporting an increase in cardiovascular events
with increases in the activity of renin, the rate-limiting
step in Ang II generation (1). The role of Ang II in the
atherogenic process has been inferred from the survival
and ventricular enlargement trial that demonstrated
that administration of ACE inhibitors was associated
with a decrease in cardiovascular morbidity and mortality (2). Also, increases in circulating angiotensin-converting enzyme (ACE) due to a DD genotype were associated with increases in cardiovascular disease (3). In
addition to increased plasma concentrations of Ang II,
evidence suggests increased local production of Ang II
within atherosclerotic lesions that express the necessary enzymes for Ang II synthesis including renin (4)
and ACE (5). Furthermore, Ang II accumulation has
been demonstrated by immunocytochemistry in
human atherosclerotic lesions (6).
Inhibitors of ACE have been studied in a number of animal models of atherosclerosis, including; cynomolgus
monkeys (7), minipigs (8), WHHL rabbits (9), cholesterolThe Journal of Clinical Investigation
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fed rabbits (10–13), hamsters (14, 15), and apoE–/– mice
(16). With the exception of one of these reports, all
demonstrated significant reductions in the extent of atherosclerosis, consistent with a role for Ang II in the disease. However, as the specific pharmacologic properties
of ACE inhibitors would influence synthesis of other
autacoids in addition to Ang II, these effects of ACE
inhibitors do not necessarily define an action of Ang II.
Further evidence can be derived from studies in Tsukuba
hypertensive mice that were created by cross breeding of
transgenic animals carrying the human angiotensinogen
and renin genes (17, 18). These mice form extensive
lesions in the aortic root during feeding of diets enriched
in saturated fat, cholesterol, and cholate (19).
Ang II has several potential mechanisms that may
increase the atherogenic process. First, Ang II may indirectly influence the atherogenic process via hemodynamic effects resulting from increased arterial blood
pressure. Marked increases in arterial blood pressure
have been demonstrated to increase the severity of experimental atherosclerosis (20). Second, Ang II has been
demonstrated to exert several direct effects relevant to
the development of atherosclerosis including stimulation of monocyte recruitment (21), activation of
macrophages (22), and enhanced oxidative stress (23), all
of which have been linked to an increase in the atherogenesis process (24). These effects of Ang II would occur
independent of elevations in arterial blood pressure.
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To define whether increased plasma concentrations
of Ang II have a direct effect on the atherogenic process,
we infused Ang II into 6-month-old apoE–/– mice in
which the disease process was already established. Our
results demonstrate that infusions of Ang II augmented the development of atherosclerosis by the formation
of new lesions composed of lipid-laden macrophages
and lymphocytes. Unexpectedly, Ang II also produced
large abdominal aortic aneurysms. These effects of Ang
II occurred independent of elevations in mean arterial
pressure or changes in plasma lipid concentration and
in lipoprotein cholesterol distribution.

Methods
Mice. Female C57BL/6J and apoE–/– mice (backcrossed
10 × into a C57BL/6J background) were obtained from
The Jackson Laboratories (Bar Harbor, Maine, USA).
All mice were maintained under barrier conditions.
Water and normal laboratory diet were available ad libitum. All procedures involving animals were approved
by the Animal Care and Use Committee at the University of Kentucky.
Infusion of Ang II. Alzet osmotic minipumps (Model
2004; ALZA Scientific Products, Mountain View, California, USA) were implanted into C57BL/6J and apoE–/–
mice at 6 months of age. Pumps were filled either with
saline vehicle or solutions of Ang II (Sigma Chemical
Co., St. Louis, Missouri, USA) that delivered (subcutaneously) either 500 or 1,000 ng/min/kg of Ang II for 28
days. Pumps were placed into the subcutaneous space
of ketamine/xylazine anesthetized mice through a
small incision in the back of the neck that was closed
with surgical glue. All incision sites healed rapidly without the need for any medication.
Determination of blood pressure. Systolic blood pressure
was obtained on a weekly basis in ketamine/xylazine
anesthetized mice using a tail cuff apparatus coupled to
a PC-based data acquisition system (RTBP1007; Kent
Scientific, Litchfield, Connecticut, USA). A minimum of
three measurements were obtained from each mouse. At
the termination of the experiment, mean arterial pressure was measured in anesthetized mice via a femoral
artery catheter coupled to the data acquisition system.
Lipids and lipoprotein characterization. Serum total cholesterol and triglyceride concentrations were determined
with enzymatic assay kits (Wako Chemical Co., Richmond, Virginia, USA). Lipoprotein cholesterol distributions were evaluated in individual serum samples (50 µL)
from four mice in each group after fractionation by fast
protein liquid chromatography (FPLC) gel filtration
(Pharmacia LKB Biotechnology, Uppsala, Sweden) on a
single Superose 6 column (25). Fractions were collected
and cholesterol concentrations were determined with an
enzymatic-based assay kit (Wako Chemical Co.).
Quantification of atherosclerotic lesions. Aortic tissue was
removed from the ascending aorta to the ileal bifurcation and placed in freshly prepared 4% paraformaldehyde in PBS overnight at room temperature. After tissue fixation, adventitial tissue was carefully removed.
1606
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The intimal surface was exposed by a longitudinal cut
through the inner curvature of the aortic arch that
extended down the whole length of the aortic tree. To
permit the arch region to be laid out flat, the greater
curvature was cut down to the level of the left subclavian artery. The tissue was laid out on a black background, and an image of the aorta was recorded.
To quantify the extent of intimal surface covered by
grossly discernible lesions, image analysis was performed
with SigmaScan (SPPS Inc., Chicago, Illinois, USA). The
extent of atherosclerotic lesions was quantified in the
arch, thorax, and abdominal regions. The regions were
defined as follows: (a) arch, from the ascending arch to 4
mm distal to the left subclavian artery; (b) thorax, from
the arch to the last intercostal artery branch; and (c) from
the thorax to the branch of the ileal bifurcation. The percent of intimal area covered by lesions was quantified by
two observers. There was routinely less than a 5% difference between the determinations of the two observers.
Histological and immunocytochemical characterization of atherosclerotic lesions. Aortic tissue was characterized either at
the root or in the abdominal section. For aortic root
analysis, mice were perfused with PBS via a cannula
placed in the left ventricle, with fluid drained from a severed right atria. The hearts from PBS-perfused mice were
severed from the aorta at the base, embedded in OCT,
and frozen. Abdominal sections of aorta were fixed
overnight in 4% paraformaldehyde in PBS before embedding in OCT. Serial (10 µm) sections from both regions
were mounted on Fisher MicroProbe slides (Fisher Scientific Co., Pittsburgh, Pennsylvania, USA). Elastin was
identified in selected sections with Verhoeff stains. Collagen and muscle cells were identified by Gimori staining. Neutral lipids were stained with Oil Red O.
For immunocytochemistry, sections were fixed by a
5-minute incubation in chilled ethanol. Endogenous
peroxidases were quenched by incubating sections in
3% H2O2 in methanol. Sections were subsequently
blocked with a 1% solution of the sera from the species

Figure 1
Arterial blood pressure determined using a catheter in the femoral
artery of anesthetized apoE–/– mice. Mice were anesthetized after 28
days of infusion of vehicle or the stated dose of Ang II. Points represent the mean of at least seven observations, and bars represent SEM.
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Figure 2
Distribution of lipoprotein cholesterol in serum during infusion of
vehicle (a), Ang II at 500 ng/min/kg (b), or Ang II at 1,000 ng/min/kg
(c). Serum (50 µL) was resolved with a Sepharose 6B column, and
cholesterol content of fractions was analyzed with commercially
available assay kits. Points represent the mean of five chromatographic separations that were performed on serum from individual
mice, and bars represent SEM.

used to generate the secondary antibody. Macrophages
were detected using a polyclonal antibody (1:10,000
dilution; Accurate Chemical & Scientific Corp., Westbury, New York, USA) and lymphocytes were detected
using a mAb against CD90 (1:30 dilution; BioSource
International, Camarillo, California, USA). Primary
antisera were incubated for 10 minutes at 37°C, followed by an incubation of a secondary biotinylated
antibody under the same conditions, and a complex of
avidin-biotin-horseradish peroxidase (Vector Laboratories, Burlingame, California, USA). Immunoreactivity was visualized by incubation with the red chromagen, aminoethyl carbozole. Nuclei were visualized by
counterstaining with aqueous hematoxylin.
Statistical analysis. The null hypothesis for the variables
measured in the groups was initially tested by ANOVA.
If a group difference was noted, post hoc testing was performed using either parametric testing for multiple
groups if the data did not fit the constraints of this form
of analysis. Otherwise they were tested using Wilcoxon
rank sum tests. All statistical analyses were performed
with SigmaStat (Jandel Scientific, San Rafael, California,
USA). Data are presented as means ± SEM.
The Journal of Clinical Investigation
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Results
Ang II infusions had no effects on peripheral parameters that
influence atherogenesis. We have previously infused Ang II
at a dose of 200 ng/min/kg into rats and have demonstrated increases in systolic pressure (by 40 mmHg),
development of cardiac hypertrophy, and a decrease in
body weight (26). In contrast, results from preliminary
studies indicated that mice required substantially higher doses of Ang II to achieve any discernible effect (data
not shown). Therefore, we chose doses of 500 and 1,000
ng/min/kg of Ang II, which were infused over 28 days in
6-month-old apoE–/– mice fed a normal diet. The Ang II
infusions were initiated in apoE–/– mice at an interval of
modest atherosclerotic lesion development (27).
Infusion of Ang II (500 or 1,000 ng/min/kg) did not
significantly alter body weight (Table 1; ref. 26). Arterial blood pressure was measured on anesthetized mice at
weekly intervals after the start of Ang II infusion. There
was no significant change in systolic blood pressure in
Ang II infused mice compared with vehicle-infused controls throughout the experimental protocol (data not
shown). On day 28 of Ang II infusion, mice were anesthetized and mean arterial pressure was obtained via a
catheter placed in the left femoral artery. Systolic, diastolic, and mean arterial pressure was not significantly
different in the groups infused with Ang II compared
with vehicle controls (Figure 1). Moreover, infusion of
Ang II tended to reduce serum concentrations of both
cholesterol and triglycerides, but neither of these
changes reached statistical significance (Table 1). In
addition, Ang II infusion did not change the distribution of cholesterol within lipoprotein fractions as determined by size exclusion chromatography (Figure 2).
Ang II increases the extent of atherosclerosis by causing newly
formed lesions composed of lipid-laden macrophage and lymphocytes. The extent of atherosclerosis was measured on
the aortic intimal surface as described previously (28).
The abdominal segment was excluded from this analysis because of the appearance of aneurysms as
described later here. There was extensive atherosclero-

Figure 3
Percent of intimal area covered by grossly discernible atherosclerotic lesions in the thoracic region. Circles represent the values for individual animals, and bars are the means for the groups. Infusion of
Ang II significantly increased the percent of lesion area in the thoracic
aorta. AStatistical difference of P > 0.05 from the control group using
a Wilcoxon’s rank sum test.
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Figure 4
Characteristics of atherosclerotic lesions from vehicle-infused apoE–/–
mice (a) and Ang II–infused mice (b–d). Tissues were immunostained
for the presence of macrophages (a–c) using an antiserum purchased
from Accurate Chemical and Scientific Corp. (1:10,000 dilution).
Lymphocytes were immunostained (d) using a CD90 antibody from
BioSource International (1:30 dilution). Tissue sections were counterstained with hematoxylin. a–c, ×200; d ×400. An arrow indicates
the medial-intimal boundary.

sis in the arch of all groups of apoE–/– mice, as may be
expected for the age of the mice. The relatively brief
infusion of Ang II did not significantly change the
extent of this established disease (data not shown). In
contrast to the arch region, apoE–/– mice infused with
vehicle had either none or very few lesions present in
the thoracic aorta. In this region, Ang II promoted a
significant increase in the extent of discernible atherosclerotic lesions in the thoracic aorta (Figure 3).
Although the mean value for the lesion quantification
was higher in the group infused with 1,000 compared
with 500 ng/min/kg of Ang II, the difference did not
attain statistical significance. In the group infused with
the higher dose (1,000 ng/min/kg) of Ang II, several of
the mice had many small lesions dispersed randomly
throughout the thoracic aorta, consistent with Ang II
(Figure 4, b–d) initiating the development of lesions.
Immunocytochemical analysis of arterial tissue from
vehicle-treated mice demonstrated that lesions had
cores that diffusely immunostained for macrophages,
although there was a low number of nuclei in this
region (Figure 4a). These characteristics of the tissue
would be consistent with the presence of nonviable
cells in the core region. Cells in the more abluminal
aspect of the lesion had a smooth muscle cell–like
appearance. Three major differences were observed in
mice infused with Ang II (Figure 4, b–d). One was the
extent of medial hypertrophy seen after Ang II infusion. Second was the pronounced presence of
macrophages in the adventitia underlying lesions
(Figure 4, a versus b). Macrophage immunostaining in
these regions was characterized by intense chromagen
development in cells that did not have overt lipid dep1608
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osition. Many of these cells were present at the boundary of the atherosclerotic intima and media. Third was
the presence of new lesions that appeared to have
formed on top of established lesions (Figure 4c). These
were characterized by lipid-laden cells that immunostained with the antimacrophage antibody. In addition,
there was a large number of lymphocytes present on
the luminal aspect of lesions (Figure 4d).
Ang II infusion promotes the development of abdominal aortic aneurysms. During removal of the aortas, it was noted
that there was substantial adventitial tissue present in
the abdominal area of the aorta in some of the apoE–/–
mice infused with Ang II. A representative aorta from an
apoE–/– mouse receiving Ang II compared with saline
vehicle controls is illustrated in Figure 5. The region in
the abdominal aorta from an Ang II–infused mouse was
markedly increased in size; moreover, the tissue encompassing this region was resistant to the dissection
process typically used to remove adventitial tissue. The
bulbous aortic abdominal shape illustrated in Figure 5
occurred in 20% and 33% of mice in the groups infused
with 500 and 1,000 ng/min/kg of Ang II, respectively. A
blood clot was present within the greatly expanded
adventitial tissue, and the neovasculature was present on
the outer surface. In contrast, in mice infused with vehicle, adventitial tissue was easily removed from the aorta.
Several of the aortic aneurysms were sectioned at 10
µm throughout the entire bulbous area of the abdominal aorta. These sections revealed two regions of dis-

Figure 5
An example of the aneurysms formed in the abdominal aorta of
apoE–/– mice infused with Ang II. The aortic segments shown are from
approximately the last intercostal branch to the ileal bifurcation. The
aorta on the right is an example from an apoE–/– mouse infused with
AngII (1,000 ng/min/kg) for 28 days. The aorta on the left is an
example from an age- and gender-matched apoE–/– mouse infused
with vehicle for the same interval.
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Table 1
Body weight and serum lipid concentration in apoE–/– mice infused with either vehicle or the stated doses of Ang II for 28 days via osmotic pumps
Group

Body weight
(g)

Serum cholesterol
concentration (mg/dL)

Serum triglyceride
concentration (mg/dL)

Control

25.3 ± 0.7

330 ± 76

45 ± 5

Ang II 500 ng/min/kg
Ang II 1,000 ng/min/kg

24.3 ± 0.4 (NS)
24.3 ± 0.5 (NS)

211 ± 6 (NS)
258 ± 21 (NS)

27 ± 4 (NS)
34 ± 7 (NS)

Values represent the mean ± SEM; n = 8–10 for all groups. NS, not significant compared with controls.

tinct characteristics. One region had intact elastin layers in the media that were associated with pronounced
remodeling in the adventitial space (Figure 6a). The
cross-sectional area of the lumen of the abdominal
aorta of these sections was similar to that of tissues of
the same region from mice not infused with Ang II.
This region of the aneurysm usually contained a blood
clot surrounded by extracellular matrix that had a
prominent collagen content (Figure 6b). Neutral lipids,
defined by Oil Red O staining, marginated to the outer
boundaries of the remodeled tissue (Figure 6c).
Immunostaining for macrophages also tended to be
marginated to the outer boundaries, although some
diffuse immunostaining was present in much of the
remodeled area (Figure 6d). The other region of the
aneurysm was characterized by a complete medial
break that resulted in marked dilation of the lumen
(Figure 6, e and f). In this region, there was thinner
adventitial area that had a relatively greater component
of neutral lipids and macrophages. In the four
aneurysms that were sequentially sectioned, small atherosclerotic lesions were observed; however, lesions
were not at the site of the abdominal aortic segments
containing the medial breaks.
Equivalent doses of Ang II do not cause vascular pathology in
apoE+/+ mice. To determine whether the Ang II–induced
promotion of atherosclerotic lesions and aneurysm formation required the hyperlipidemic state present in
apoE–/– mice, Ang II infusions (500 and 1,000
ng/min/kg) were performed in apoE+/+ mice of the equivalent strain; C57BL/6J. As with the apoE–/– mice, systolic
blood pressure was measured weekly using a tail cuff and
was not significantly altered throughout Ang II infusion
(data not shown). Systolic and diastolic arterial measurements obtained via a femoral artery catheter on day
28 of Ang II infusion also failed to demonstrate any significant change (Table 2). As may be expected, there were
no discernible atherosclerotic lesions in these normolipidemic C57BL/6J mice infused with either of the
doses of Ang II. Furthermore, no aneurysms were
observed. However, Ang II promoted medial hypertrophy as already described here in the apoE–/– mice.

Discussion
This study was designed to determine whether increases in circulating plasma concentrations of Ang II were
associated with an increase in the extent of atherosclerosis. All experiments were performed in apoE–/– mice
The Journal of Clinical Investigation
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that develop hyperlipidemia and relatively complex
atherosclerotic lesions when fed normal laboratory
diets (29, 30). In agreement with previous studies, the
most prominent regions for lesion development in
apoE–/– mice used in this study at 7 months of age were
the aortic root and arch (27). Small lesions were present near the renal arteries, whereas the majority of the
thoracic aorta was relatively lacking in lesions even at
intercostal branch points. After relatively short intervals (28 days) of Ang II infusion, there were several
changes in vascular pathology including an increase in
the extent of atherosclerosis, a change in the nature of

Figure 6
Characteristics of aneurysmal tissue in the abdominal aorta of
apoE–/– mice infused with Ang II. Sections are stained or immunostained with the following methods: (a) Verhoeff ; (b) Gimori; (c) Oil
Red O; (d) presence of macrophages using antisera from Accurate
Chemical and Scientific Corp. (dilution 1:10,000) and counterstained with hematoxylin; (e) Oil Red O; and (f) presence of
macrophages as in d. ×200.
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Table 2
Systolic and diastolic arterial pressure measured using a femoral artery
catheter in groups of wild-type C57BL/6 mice infused with either vehicle or the stated dose of Ang II for 28 days via osmotic pump
Group

Control
Ang II 500 ng/min/kg
Ang II 1,000 ng/min/kg

Systolic arterial
pressure
(mmHg)
85 ± 10
56 ± 17 (NS)
53 ± 9 (NS)

Diastolic arterial
pressure
(mmHg)
78 ± 10
48 ± 17 (NS)
40 ± 7 (NS)

Values represent the mean ± SEM; n = 5 for all groups. NS, not significant
compared with controls.

lesions and adventitial tissue underlying lesions, and
the formation of large abdominal aortic aneurysms.
These vascular alterations occurred in the absence of
changes in plasma cholesterol concentration and distribution and independent of Ang II–mediated increases in arterial blood pressure. The promotion of vascular pathology required the hyperlipidemic state, as
atherosclerosis and aneurysm formation were not
observed in strain-matched apoE+/+ mice.
Although Ang II is a potent hypertensive agent, we
were unable to detect a sustained increase in arterial
blood pressure over a 4-week period of Ang II infusion
at doses previously demonstrated to elevate blood pressure in rats chronically (26). Measurements of systolic
pressure were performed in anesthetized mice using a
tail cuff system. Although this technique has been used
previously to define blood pressure in conscious mice
(31, 32), a substantial interval of training of conscious
mice is required before stable measurements are
obtained (33). An additional barrier prohibiting conscious measurements of systolic pressure in the present
study included the use of C57BL/6 mice, which are
known for their high locomotor activity and resistance
to restraint (34). To validate systolic pressure measurements using a tail cuff, we measured arterial pressure in
anesthetized mice on the final day of the study through
a catheter placed in the femoral artery. Measurements
of mean arterial pressure obtained in apoE–/– mice were
in agreement with previously published values (35).
Measurements obtained by femoral artery catheter confirmed that Ang II infusion did not increase blood pressure in apoE–/– mice, in agreement with results obtained
by the tail cuff method. Statistical analysis of these data
did not fulfill the constraints of equivalence variance
and normal distribution to be analyzed by parametric
statistics in the post hoc ANOVA tests. Consequently,
we used the Wilcoxon rank sum test, which is considerably less sensitive than parametric analysis. Using this
test, there were no statistically significant changes.
Potential mechanisms contributing to the lack of a
hypertensive effect of Ang II in mice include a high
endogenous Ang II concentration due to the presence
of two renin genes (36), rapidly developing tolerance to
Ang II (37), compensatory cardiovascular reflexes elicited in response to Ang II, or regulation of Ang II recep1610
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tors after chronic Ang II exposure (38). Taken together,
our results demonstrate that the observed effects of Ang
II infusion on vascular pathology were unrelated to elevations of arterial blood pressure.
Ang II promoted several changes in the cellular characteristics of aortic tissue and atherosclerotic lesions.
Despite a lack of effect of Ang II on arterial blood pressure, medial hypertrophy was noted in the aortas of
both apoE–/– and apoE+/+ mice. Nonpressor doses of Ang
II have been previously shown to promote hypertrophy
(39). Ang II also provoked marked proinflammatory
responses in the perimedial area, manifest as an accumulation of macrophages at the external elastic lamina. This effect is consistent with a chemoattractant
property of Ang II (40). The most marked change in
atherogenesis was the formation of new lesions that
were adjacent to the mature fibrolipid lesions that had
formed in these 7-month-old apoE–/– mice. The most
prominent feature of these newly formed lesions was
lipid-laden cells that immunostained for macrophages.
Unlike the core region of established lesions, these
newly formed lesions contained many nuclei. Another
prominent feature of the lesions that formed during
Ang II infusion was the presence of a large number of
lymphocytes; a cell type that has a hypothesized,
although unproved, role in atherogenesis (41, 42). We
have previously reported that the relative number of T
lymphocytes decreases as lesions evolve in apoE–/– mice,
which is consistent with the presence of the large number of this cell type in these newly formed lesions (43).
There are several potential mechanisms by which Ang
II could augment the atherogenic process. Ang II is
thought to increase atherosclerosis through hemodynamic effects, and its attendant changes in shear stress
could influence the atherogenic process (44). Indeed,
there is accelerated lesion formation in transgenic mice
with hypertension resulting from an activated renin
angiotensin system (19). These mice had marked
increases in systolic arterial blood pressure that accompanied the increase in the extent of Oil Red O–stained
area in the aortic root. In the present study, we were
unable to detect any sustained increase in arterial pressure after chronic Ang II infusion, suggesting that
hemodynamic influences of Ang II were not paramount
in Ang II augmentation of the atherogenic process.
A number of direct effects of Ang II have been suggested to contribute to the atherogenic process including stimulation of monocyte/macrophage recruitment
and activation (21, 45). A potential mediator of this
activity is monocyte chemoattractant protein-1 (MCP1; refs. 46, 47). There is considerable evidence supporting a role for MCP-1 in atherogenesis. MCP-1 has the
ability to chemoattract macrophages (48) and lymphocytes (49), both of which are prominent cell types in atherosclerotic lesions (41, 50). Also, MCP-1 protein is present in atherosclerotic lesions from both humans and
experimental animals (51). Definitive evidence supporting a role for this cytokine has come from genetically engineered mice that are deficient in MCP-1 and
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exhibit reduced severity of atherosclerosis when crossbred to LDL receptor–/– mice (52) or apolipoprotein B
transgenic mice (53). Furthermore, deficiency of the
major MCP-1 receptor, CCR-2, reduced the extent of
atherosclerosis in apoE–/– mice (54). Previous studies
have demonstrated that Ang II promotes the elaboration of MCP-1 from endothelial cells and smooth muscle cells (46). There have been no studies demonstrating
an effect of Ang II on the release of MCP-1 from
macrophages, even though this cell type is the major
loci for accumulation of MCP-1 in lesions (51). However, the recent demonstration of Ang II activating the
transcription factor NF-B in monocytes is consistent
with an ability to promote secretion of this chemokine
(55). In Ang II–infused mice, we observed newly formed
lesions, some of which were located on top of existing
lesions that consisted of lipid-laden macrophages and
lymphocytes. These characteristics are consistent with
Ang II–promoting MCP-1 expression.
Aneurysms of the abdominal aorta represent a significant cardiovascular risk. Despite the common occurrence
of this vascular disease, the mechanism(s) that leads to
the pathology remains undefined (56). Aneurysms of the
abdominal aorta have been demonstrated previously in
apoE–/– mice (57, 58). The formation of aneurysms in
apoE–/– mice was suggested to relate to the activity of metalloelastase or metalloprotease-12 (58). However,
aneurysms previously observed in the apoE–/– model
encompassed modest dilations that did not produce total
disruption of the media and did not exhibit pathology
similar to that seen in humans (57, 58).
Aneurysms and aortic rupture have been noted in
hypertensive mice that overproduce Ang II, although
only when mice were placed on high sodium chloride
containing water (59). There are some clinical and experimental links of Ang II to aneurysm formation. For
example, gene polymorphism of ACE has also been associated with the development of aneurysms (60). Experimentally, specific strains of rats exhibit rupture of the
internal elastic lamina by a process that is abrogated by
ACE inhibitors (61). Also, salt loading the Tsukuba
hypertensive mouse lead to rupture of the aorta at the
arch and abdominal sites (59). The changes in vascular
pathology in Tsukuba mice during salt loading occurred
independent of changes in arterial blood pressure. However, these previously observed aortic aneurysms do not
provide the complex tissue remodeling in the adventitia
that are characteristic of the human disease. In contrast,
infusion of Ang II into apoE–/– mice promoted the
appearance of blood clots and tissue remodeling surrounding an area of marked adventitial hypertrophy.
Pronounced luminal dilations were also present. Of
note, the complex morphology of the aneurysms formed
in response to Ang II occurred in the absence of a measurable increase in blood pressure.
We performed sequential sectioning through the
entire aneurysm of several abdominal aortae. In no case
were we able to demonstrate the presence of an atherosclerotic lesion at or close to the site of the medial
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break. However, it is possible that a lesion present at the
aneurysm site may have been resorbed into the perimedial tissue after the rupture. Although no atherosclerotic lesions could be detected at the site of media
break, no aneurysms were detected when the identical
study was performed in the background strain to the
apoE–/– mice; C57BL/6. ApoE has many biologic properties in addition to its effects on plasma lipoprotein
metabolism (62). However, it appears that the hyperlipidemic state is augmented with the responsiveness
of Ang II, as we have also noted the presence of aortic
abdominal aneurysms in LDL receptor–/– mice fed a saturated-fat-and-cholesterol–containing diet (63).
In conclusion, we have demonstrated that short intervals of Ang II infusion into apoE–/– mice with established atherosclerosis leads to augmented lesion formation and the unexpected development of abdominal
aorta aneurysms. Further studies will define the mechanism by which Ang II exerts these effects.
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